World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ANZCTR
Last refreshed on: 13 January 2020
Main ID:  ACTRN12616001273471
Date of registration: 09/09/2016
Prospective Registration: No
Primary sponsor: sanofi Romania
Public title: The impact of a structured diabetes education program for improving glycemic control in adults with type 2 diabetes
Scientific title: The assessment of the impact of a structured diabetes education program on glycaemic control in adult type 2 diabetes patients at initiation of basal insulin analogue
Date of first enrolment: 22/10/2014
Target sample size: 750
Recruitment status: Completed
URL:  https://anzctr.org.au/ACTRN12616001273471.aspx
Study type:  Interventional
Study design:  Purpose: Educational / counselling / training; Allocation: Randomised controlled trial;  
Phase: 
Countries of recruitment
Romania
Contacts
Name: Dr Cornelia Bala   
Address:  Iuliu Hatieganu University of Medicine and Pharmacy Department of Diabetes, Nutrition, Metabolic Diseases 2 Clinicilor St, 400 006 Cluj-Napoca, Romania
Telephone: +40722605501
Email: cbala@umfcluj.ro
Affiliation: 
Name: Dr Cornelia Bala   
Address:  Iuliu Hatieganu University of Medicine and Pharmacy Department of Diabetes, Nutrition, Metabolic Diseases 2 Clinicilor St, 400 006 Cluj-Napoca, Romania
Telephone: +40722605501
Email: cbala@umfcluj.ro
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: 1. adults diagnosed with T2 DM
2. patients treated with stable doses of oral antidiabetics drugs (OADs) ( the dose was not modified in the last 3 months)
3. the diabetes is inadequately controlled with OADs and at investigator decision the patient is initiated on basal insulin analogues
4. the determination of HbA1c value must be available at the moment of the initiation of basal insulin analogues (determined in the last month)
5. Informed Consent Form signed

Exclusion criteria: The patient
1.was pregnant or breast-feeding or intented to be pregnant during the study
2.was treated with any systemic corticosteroid
3.was already included in other studies
4.had any contraindication to insulin treatment
5.patients not able to comply with - visit schedule


Age minimum: 18 Years
Age maximum: 75 Years
Gender: Both males and females
Health Condition(s) or Problem(s) studied
Metabolic and Endocrine - Diabetes
type 2 diabetes mellitus;
type 2 diabetes mellitus
Intervention(s)
In enhanced educational group
- Curriculum Modules 1: information about the importance of glycaemic control, diabetes complications video, reinforce the need of life style changes, how insulin works, training about device, glucometers and self monitoring blood glucose (SMBG), hypoglycaemia and titration+ brochure - guideline for patients realized by Romanian Association od Education in Diabetes - 45 minutes, provided by a trained nurse, in the first week after first visit, in physician office, one-on-one discussion
- Curriculum Modules 2: a short interview with patients about his/her knowledge and changes that he/her has done in the past 3 months; reinforce the information which was not very well understood, check SMBG diary and insulin titration algorithm; education about insulin treatment complication and the possibility of intensification need (how to check postprandial glycaemia) - 45 minutes, provided by a trained nurse in the first week after visit 2, in physician office, one-on-one discussion

All enrolled patients have performed 3 medical visits( first - baseline, at initiation, second - after 3 months, third - after 6 months); the data has been collected by the Investigators in the Case Report Forms (CRFs) and, on visits 1 and 3, the patients filled-in “EQ5D” and “Diabetes Empowerment Scale (DES”) questionnaires.
Not specific strategies used to monitor adherence
Primary Outcome(s)
the changes of HbA1c from baseline to the end of study in both groups
with structured education and control group[6 months after first visit]
proportion of patients reaching individualized target of HbA1c (established a priori by the physician) in each group (with / without enhanced education)[6 months after the first visit]
Secondary Outcome(s)
the incidence of confirmed symptomatic (<70 mg/dl) hypoglycemic episodes at the end of study for both groups - in number of events - measured by SMBG[6 months after enrollment]
the incidence of confirmed symptomatic (<70 mg/dl) hypoglycemic episodes at the end of study for both groups - in number of patients that experienced at least one hypoglycemic events - measured by SMBG[6 months after enrollment]
the incidence of severe hypoglycemic episodes (required third assistance) at the end of study for both groups in number of events - from patients interview or documented if was necessary the hospitalization [6 months after enrollment]
the incidence of severe hypoglycemic episodes (that required third assistance) at the end of study for both groups - in number of patients that experienced at least one hypoglycemic events - from patients interview or documented if was necessary the hospitalization [6 months after enrollment]
Secondary ID(s)
Identifiers assigned by the sponsor: DIREGL07301
Source(s) of Monetary Support
Sanofi
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Romanian National Ethic Committee
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history